Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. Pfizer

30.6% sales growth and 11.06% return on equity

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide.

Pfizer’s sales growth this year is expected to be 48.3% and a negative 14.2% for next year.

Year-on-year quarterly revenue growth declined by 7.9%, now sitting on 41.91B for the twelve trailing months.

Pfizer’s sales growth for the next quarter is 30.6%. The company’s growth estimates for the ongoing quarter and the next is a negative 2.5% and 9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.06%.

Volatility

Pfizer’s last day, last week, and last month’s current volatility was 1.01%, 0.79%, and 0.79%, respectively.

Pfizer’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.93% (day), 1.54% (last week), and 1.56% (last month), respectively.

Pfizer’s Stock Yearly Top and Bottom Value

Pfizer’s stock is valued at $37.16 at 08:22 EST, way below its 52-week high of $43.08 and way higher than its 52-week low of $29.99.

Pfizer’s Moving Average

Pfizer’s worth is higher than its 50-day moving average of $34.97 and higher than its 200-day moving average of $35.99.

Previous days news about Pfizer

According to Bloomberg Quint on Friday, 9 April, "The White House has long signaled that J&J’s ramp-up will take time and the supply will vary from week to week, as was the case with the other vaccines authorized in the U.S. by Pfizer Inc. and its partner BioNTech SE, and Moderna Inc., both of which require two doses.", "Overall, U.S. shipments in the coming week will total 28 million doses, down from 33 million a week earlier, with Pfizer and Moderna still accounting for the vast majority of U.S. shipments. "

Pfizer, biontech seek to expand covid vaccine use to young teens. According to Bloomberg Quint on Friday, 9 April, "In the study of 2,260 adolescents, the vaccine produced antibodies against Covid-19 that exceeded the level seen in vaccinated young adults, Pfizer and BioNTech said in a statement on March 31. ", "In March, both Pfizer and the maker of the other mRNA vaccine against the coronavirus, Moderna Inc., began trials for their vaccines in children under age 12."

According to Bloomberg Quint on Friday, 9 April, "France has approved Pfizer and BioNtech, and Moderna vaccines based on this technology."

Australia secures additional 20 million Pfizer vaccine doses. According to Bloomberg Quint on Friday, 9 April, "The Australian government said it has secured an additional 20 million doses of the Pfizer vaccine, amid concerns about blood clotting associated with AstraZeneca Plc’s Covid-19 shot.", "Prime Minister Scott Morrison said the extra supplies meant Australia would have access to 40 million Pfizer doses this year."

3. Northwest Pipe Company

6% sales growth and 7.36% return on equity

Northwest Pipe Company, together with its subsidiaries, manufactures and supplies engineered welded steel pipe systems in North America.

Northwest Pipe Company’s sales growth this year is expected to be 6.2% and 5.3% for next year.

Year-on-year quarterly revenue growth declined by 4%, now sitting on 285.91M for the twelve trailing months.

Northwest Pipe Company’s sales growth for the next quarter is 6%. The company’s growth estimates for the ongoing quarter and the next is a negative 48.5% and 2.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.36%.

Volatility

Northwest Pipe Company’s last day, last week, and last month’s current volatility was 4.06%, 1.67%, and 1.86%, respectively.

Northwest Pipe Company’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 5.91% (day), 3.16% (last week), and 3.66% (last month), respectively.

Northwest Pipe Company’s Stock Yearly Top and Bottom Value

Northwest Pipe Company’s stock is valued at $32.99 at 08:22 EST, way below its 52-week high of $38.08 and way above its 52-week low of $19.33.

Northwest Pipe Company’s Moving Average

Northwest Pipe Company’s value is below its 50-day moving average of $33.85 and above its 200-day moving average of $30.22.

4. Enova International, Inc.

6.7% sales growth and 58.39% return on equity

Enova International, Inc., a technology and analytics company, provides online financial services.

Enova International, Inc.’s sales growth this year is expected to be 12.7% and 30.7% for next year.

Year-on-year quarterly revenue growth declined by 33.6%, now sitting on 597.5M for the twelve trailing months.

Enova International, Inc.’s sales growth for the next quarter is 6.7%. The company’s growth estimates for the present quarter and the next is 392.3% and negative -45.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 58.39%.

Volatility

Enova International, Inc.’s last day, last week, and last month’s current volatility was 0.23%, 0.95%, and 2.48%, respectively.

Enova International, Inc.’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.93% (day), 3.00% (last week), and 4.36% (last month), respectively.

Enova International, Inc.’s Stock Yearly Top and Bottom Value

Enova International, Inc.’s stock is valued at $34.32 at 08:22 EST, way under its 52-week high of $41.06 and way higher than its 52-week low of $9.43.

Enova International, Inc.’s Moving Average

Enova International, Inc.’s value is under its 50-day moving average of $34.82 and way above its 200-day moving average of $25.20.

LEAVE A REPLY

Please enter your comment!
Please enter your name here